Physician profile
Mary Cook
NPI 1639600620
$811.90
in general payments reported to CMS, 2019-2025
11 companies · $414 in 2025
The $414 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $95.00 · 2023: $201 · 2024: $102 · 2025: $414.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $717.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $716.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $178.19 | 2023 | Trodelvy |
| Daiichi Sankyo INC. | $169.99 | 2024-2025 | Datroway, Enhertu |
| Novartis Pharmaceuticals Corporation | $99.08 | 2024-2025 | |
| Seagen INC. | $95.00 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $67.51 | 2024-2025 | Calquence |
| E.R. Squibb & Sons, L.L.C. | $54.78 | 2024-2025 | Opdivo |
| Janssen Biotech, INC. | $40.95 | 2025 | Rybrevant |
| Glaxosmithkline, LLC. | $32.66 | 2025 | Ojjaara |
| Merck Sharp & Dohme LLC | $26.10 | 2025 | Keytruda, Welireg |
| Celgene Corporation | $24.73 | 2025 | Reblozyl |
| Genentech USA, INC. | $22.91 | 2023 | Columvi, Polivy, Lunsumio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Cook listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.